This study investigates the use of an investigational medication as a treatment for locally advanced pancreatic cancer.
The focus is on evaluating the treatment's effects in patients with this condition.
- Who can participate: Adults aged 18 to 70 with confirmed pancreatic ductal adenocarcinoma and no prior pancreatic tumor resection, chemotherapy, targeted, or immunotherapy can participate. Participants must have a good performance status and meet specific health criteria.
- Study details: Participants will receive an investigational medication every two weeks. A placebo may be used. The study will include regular assessments to monitor health and response to the treatment.